Foresite Capital Management V, LLC — 13F Holdings & Portfolio
CIK 1792206 · latest 13F-HR filed 2026-08-14
Foresite Capital Management V, LLC manages $362.2M in 13F-reported U.S. long-equity assets across 9 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are ALMS (45.81%), CGON (21.17%), IRON (7.55%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 1 new position and exited 1; 7 existing positions rose in reported value and 1 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-08-14
vs 2026-03-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
| Name | Title / Status | Ownership | Type |
|---|
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- ALUMIS INC.$36.0M +27.7%
- Pharvaris N.V.$17.5M +318.8%
- Hims & Hers Health, Inc.$10.3M +67.0%
- CG Oncology, Inc.$8.7M +12.8%
- Disc Medicine, Inc.$3.4M +14.4%
Foresite Capital Management V, LLC Holdings (2026-06-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | ALUMIS INC. | ALMS | 022307102 | $165.9M | 45.81% | 5,896,995 | SH |
| 2 | CG Oncology, Inc. | CGON | 156944100 | $76.7M | 21.17% | 1,079,050 | SH |
| 3 | Disc Medicine, Inc. | IRON | 254604101 | $27.4M | 7.55% | 374,069 | SH |
| 4 | Hims & Hers Health, Inc. | HIMS | 433000106 | $25.6M | 7.07% | 738,151 | SH |
| 5 | Pharvaris N.V. | PHVS | N69605108 | $23.0M | 6.34% | 664,142 | SH |
| 6 | Eikon Therapeutics, Inc. | EIKN | 282564103 | $17.2M | 4.75% | 1,318,983 | SH |
| 7 | Odyssey Therapeutics, Inc. | ODTX | 67613T104 | $13.3M | 3.68% | 713,105 | SH |
| 8 | Lyell Immunopharma, Inc. | LYEL | 55083R203 | $6.7M | 1.85% | 476,386 | SH |
| 9 | Nurix Therapeutics, Inc. | NRIX | 67080M103 | $6.4M | 1.77% | 265,000 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $362.2M | 9 | 0001104659-26-097121 |
| 2026-03-31 | 2026-05-15 | $271.0M | 9 | 0001104659-26-062464 |
| 2025-12-31 | 2026-02-17 | $164.4M | 7 | 0001104659-26-015410 |
| 2025-09-30 | 2025-11-14 | $108.7M | 6 | 0001104659-25-112503 |
SUITE PH1
WEST HOLLYWOOD, CA 90069